June 2, 2016
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Onconova Announces Upcoming Rigosertib Clinical Trial Presentations for2016 ASCO Annual Meeting
TOKYO, Japan, June 2, 2016 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo,“SymBio”) announced today that its U.S. partner, Onconova Therapeutics, Inc.
(Headquarters: Newtown, PA, “Onconova”) announced on May 31, 2016 (EST) thedetails of its two poster presentations for the 2016 American Society of ClinicalOncology (“ASCO”) Annual Meeting to be held from June 3-7, 2016 in Chicago, Illinois.
The presentations are “Rationale and Mechanism of Action for Rigosertib/Azacitidine
Combination Therapy”, to be presented on Monday, June 6, 2016 from 8:00 AM - 11:30
AM, and “Design of Phase 3 INSPIRE Trial for Second-line Higher-risk Myelodysplastic
Syndromes” to be presented on Monday, June 6, 2016 from 8:00 AM - 11:30 AM.
SymBio obtained the licensing rights for rigosertib in July, 2011 and retains thedevelopment rights for Japan and Korea.
For more details in this press release, please visit Onconova’s homepage at
http://investor.onconova.com/releases.cfm[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125
About Myelodysplastic Syndromes (MDS)MDS patients often require frequent blood transfusions due to the development ofsevere anemia (decrease in the number of red blood cells), with a high rate of

progression to acute myelogenous leukemia (AML). There are an estimated 11,000 MDS
patients in Japan alone, with the number of cases expected to increase as thepopulation ages. MDS and AML are widely recognized as two blood disorders that aredifficult to manage given the limited therapeutic options available for patients,
particularly for patients who have a drug-resistant form of the disease. A high unmet
medical need clearly exists for the establishment of new effective therapies to treat both
lower-risk MDS and higher-risk MDS.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on
discovering and developing novel products to treat cancer. Onconova's clinical andpre-clinical stage drug development candidates are derived from its extensive chemical
library and are designed to work against specific cellular pathways that are importantin cancer cells, while causing minimal damage to normal cells. In addition to rigosertib,
Onconova's most advanced drug candidate under development, two other drugcandidates are in clinical trials and several other compounds in the pre-clinical stage ofdevelopment. For more information, please visit http://www.onconova.com.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida
who previously served concurrently as Corporate VP of Amgen Inc. and foundingPresident of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned
subsidiary in the United States, called SymBio Pharma USA, Inc. (Headquarters:Menlo Park, California, USA, President: Mr. Fuminori Yoshida).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as
it aspires to be a leading global specialty biopharmaceutical company dedicated toaddressing underserved medical needs with main therapeutic focus in oncology,
hematology and pain management.